Fuso Chemical Co., Ltd. Overview
| Item | Detail | Source / Note |
|---|---|---|
| Legal name | 扶桑化学工業株式会社 / FUSO CHEMICAL CO., LTD. | Annual Securities Report FY2026 cover page |
| Former names | None identified for the parent. Subsidiary Qingdao Fuso No.2 Refining & Processing was renamed Fuso Chemical (Qingdao) in Nov 2008. | EDINET history section |
| Founded | 24 June 1957. It was spun out of the Osaka plant of Teikoku Seiyaku Co., Ltd. with capital of JPY 2 M. | Annual Securities Report history; company 2019 retrospective |
| Incorporation jurisdiction | Japan (Osaka) | Annual Securities Report |
| Registered head office | Nippon Life Yodoyabashi Bldg. 16F, 3-5-29 Kitahama, Chuo-ku, Osaka 541-0041. Relocated here in Sep 2023. | Annual Securities Report FY2026; recruitment disclosures |
| Second head office | Tokyo Head Office, Ogura Bldg. 7F, 6-6 Nihonbashi Kobunacho, Chuo-ku, Tokyo | Company recruitment pages |
| Exchange / ticker | Tokyo Stock Exchange Prime Market, code 4368. History: JASDAQ OTC in 2001, JASDAQ in 2004, TSE 1st Section from 7 Dec 2015, Prime from 4 Apr 2022. | J-LIC listing history; EDINET |
| ISIN | The Japanese ISIN for code 4368 should be confirmed with JPX or a vendor. | — |
| CUSIP | Not applicable. No ADR programme was identified. | — |
| Fiscal year end | 31 March | Annual Securities Report |
| Share capital | JPY 4,334 M | Company recruitment disclosure |
| Employees (consolidated) | 956 at FY2026. A non-consolidated trend appears in table 1.3. | Annual Securities Report FY2026 via The Shashi |
| Auditor | Ernst & Young ShinNihon LLC. FY2026 audit fees were JPY 47 M (JPY 42 M for the parent plus JPY 5 M for network firms). | J-LIC; Annual Securities Report via The Shashi |
| Governance form | Company with an Audit & Supervisory Committee (監査等委員会設置会社), adopted Jun 2018 | Corporate Governance Report, May 2026 |
| Representative directors | Shinichi Sugita (President & CEO); Misako Fujioka (Chairman) | Annual Securities Report; AGM notice Jun 2026 |
| Market capitalisation | About JPY 343.0 bn at ¥3,220 per share (close 30 Sep 2026) | Monex Scouter |
| Shares outstanding | About 106.5 M post-split. Derived as market cap ÷ price; Traders Web cites roughly 107 M shares issued. | Derived |
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Employees, non-consolidated (persons) | 491 | 538 | 567 | 588 | 623 |
| Employees, consolidated (persons) | — | — | — | — | 956 |
| Average annual salary, non-consolidated (JPY 10k) | 678 | 716 | 713 | 725 | 758 |
Notes on the table:
Source: Annual Securities Reports, compiled by The Shashi.
- One broker profile shows 930, which probably relates to FY2025.
Segment split of FY2026 headcount: - Electronic Materials: 384
-
Life Science: 516
-
Corporate: 56
Fuso Chemical is an Osaka-based "global niche top" specialty chemical company. It runs two businesses with very different economics.
The first is Electronic Materials. Its core product is ultra-high-purity colloidal silica, sold under the Quartron® brand. This is the nano-abrasive raw material that CMP-slurry makers formulate into slurries used to polish silicon wafers and planarize interconnect layers in advanced logic and memory. Several third-party studies describe Fuso as the world's leading supplier of this product, although their share estimates differ widely. In FY2026 the segment produced 54% of sales but about 75% of segment profit, at a 38.4% operating margin.
The second is Life Science. Fuso is a vertically integrated fruit and organic acid producer with plants in Japan, China, Thailand and the US. Products include malic, citric and gluconic acid, maleic anhydride, fumaric acid, and food-additive preparations. Fuso holds a leading global position in malic acid.
The balance sheet is conservative: a 77% equity ratio and net cash. The investment case now rests on AI-driven semiconductor demand, a JPY 40 bn capacity build at Kyoto due in Feb 2029, and the "Next Growth 2030" plan, which targets JPY 120 bn of sales and JPY 36 bn of operating profit by FY2031.
What the company does: the company's own characterisation (paraphrased)
The Annual Securities Report describes the group as two reportable segments:
Life Science: manufactures and sells fruit acids, organic acids and applied/derivative products for food, beverage, industrial and pharmaceutical uses.
Electronic Materials: manufactures and sells ultra-high-purity colloidal silica and related silica functional materials, mainly for semiconductor polishing.
The corporate motto is 「限りなき進歩と創造」 ("endless progress and creation"). The company states two aspirations:
-
to pursue a "global niche top" position with many "gold-medal" products in specific fields;
-
to contribute to richer lives and a sustainable future.
Independent characterisation
Fuso is effectively two companies sharing one balance sheet.
Electronic Materials: a near-monopoly-like raw-material position. Fuso makes very high-purity colloidal silica by alkoxide-based synthesis (hydrolysis of high-purity silicon alkoxide). This gives exceptional control of:
-
metal impurities;
-
particle-size distribution;
-
coarse-particle counts, a central quality attribute for CMP.
Its patents cover:
-
silica particles with controlled alkoxy-group content;
-
particles with bent or branched structures;
-
particles of 60–130 nm average size with coarse-particle counts held below defined thresholds.
Fuso sells this abrasive raw material to slurry formulators. It does not sell to fabs directly. That places it one tier upstream of the CMP-slurry market and two tiers upstream of the fabs. Its largest disclosed customer is FUJIFILM Electronic Materials Taiwan Co., Ltd., which accounted for:
-
13.9% of consolidated sales in FY2026;
-
12.9% (JPY 8,994 M) in FY2025;
-
15.3% (JPY 9,010 M) in FY2024.
Qualification cycles at slurry makers and fabs are long. That creates high switching costs, but it also slows the conversion of new capacity into sales.
Life Science: a cyclical, more commoditised fruit-acid business with local-for-local production.
Malic acid: made in Osaka (Sakai) and Kashima. Fuso is described as a world-top-class producer.
Citric acid: imported crude citric acid is refined in Qingdao, China, to meet Japanese food-additive specifications. This model dates from the late 1980s, when Chinese crude product often failed Japanese standards.
Gluconic acid and sodium gluconate: produced by PMP Fermentation Products in Peoria, Illinois, USA. Uses include concrete admixtures and metal treatment.
Maleic anhydride and fumaric acid: taken over from Mitsui Chemicals in Oct 2014.
Higher-margin formulations: food-additive preparations such as shelf-life, noodle, deli and tofu preparations; coated organic acids; and high-purity organic acids.
Revenue model
| Dimension | Characterisation |
|---|---|
| Product vs service vs subscription vs licensing | Essentially 100% product sales. No material service, subscription or licensing revenue is disclosed. |
| Pricing | Negotiated B2B pricing. Electronic Materials pricing is set customer by customer under qualification-based supply agreements. Life Science pricing tracks raw-material costs (corn and sugar feedstocks, petrochemical inputs for maleic/fumaric, Chinese crude citric acid) and FX. Daiwa Securities' initiation (Outperform, 2026) argued that price increases are letting Fuso escape a "supply-responsibility vs profitability" dilemma. That is a broker view, not a company disclosure. |
| Value-chain position | Electronic Materials: Tier-2 materials supplier (raw abrasive → slurry maker → fab). Life Science: ingredient manufacturer and refiner (feedstock → acid → food/beverage, industrial and pharma customers). |
| Customer types | Electronic Materials: CMP-slurry formulators (Fujifilm group and others; most names undisclosed). Life Science: food and beverage makers, food-ingredient distributors, concrete-admixture and metal-treatment users, pharma. |
| End-markets | Semiconductors, especially AI logic and HBM/DRAM requiring advanced CMP steps. Silicon-wafer polishing. Toner, anti-reflective coatings and insulation (new silica applications). Processed food and beverages. Construction (gluconates). Metal processing. |
| Geographic mix FY2026 | Japan 44.9%, Asia 38.3%, North America 15.8%, Europe 0.9%, Other 0.1%. Overseas ratio 55.1%. |
Strategy
Previous plan: "FUSO VISION 2025" (FY2022–FY2026)
| Target (final year FY2026) | Original plan (JPY Mn) | Revised plan May 2023 (JPY Mn) | FY2026 actual (JPY Mn) | Status |
|---|---|---|---|---|
| Net sales | 58,000 | 85,000 | 76,926 | Missed by about 9.5% |
| Operating profit | 14,000 | 19,000 | 18,850 | Essentially met |
| EBITDA | 20,000 | 30,000 | 29,787 | Essentially met |
| Overseas sales ratio (%) | — | 50 | 55.1 | Exceeded |
Announced May 2021; targets raised May 2023.
The plan also included R&D investment of JPY 2 bn; the basis (annual or cumulative) is not clarified in the sources reviewed. Its three management themes were:
-
capture expanding demand in existing businesses;
-
invest in and challenge new businesses and fields;
-
strengthen the management base for sustainable growth, including the SDGs.
New plan: "飛躍2030 / Next Growth 2030" (FY2027–FY2031)
| Target | FY2026 actual | FY2031 target | Implied 5-yr CAGR | Source |
|---|---|---|---|---|
| Net sales (JPY M) | 76,926 | 120,000 | 9.3% | Tanshin / plan via FilingReader |
| Operating profit (JPY M) | 18,850 | 36,000 | 13.8% | Same |
| EBITDA (JPY M) | 29,787 | 56,700 | about 13.7% (derived) | Same |
| ROIC (%) | 11.1 | ≥13 | — | Corporate presentation, Aug 2026 |
| ROE (%) | 12.9 | >10, maintained | — | Same |
| P/B (x) | about 2.5 (Mar 2026) | 2.5 (KPI) | — | Same |
The document is dated 15 May 2026.
Data conflict. Envalith describes the JPY 36 bn target as ordinary profit. FilingReader's summary and the stated 13.8% CAGR, which reconciles exactly to FY2026 operating profit, indicate it is operating profit.
Strategic themes (paraphrased from the plan, presentations and the Annual Securities Report)
1. Electronic Materials: capacity, qualification, technology.
-
Ramp Kashima Phase 2 through customer qualification.
-
Fill the new Kyoto line. It was qualified earlier than expected and moved to full-scale operation around end-FY2026.
-
Build the JPY 40 bn Kyoto plant (Mar 2026 to Feb 2029). The Mar 2026 disclosure said it would be self-funded. Envalith notes possible use of long-term borrowings.
-
Develop products for finer, multi-layer and higher-performance devices.
2. Diversification of silica. Hollow nano-silica and other new functional materials, explicitly to reduce dependence on semiconductors (Annual Securities Report risk response).
3. Life Science: value-add and overseas.
-
Expand coated organic acids and food-additive preparations.
-
Grow malic-acid share in the US.
-
Expand sodium gluconate at PMP.
4. Capital efficiency.
-
ROIC-based decision framework.
-
Cost of equity estimated at 8–9%.
-
Corporate Value Enhancement Committee.
-
Enhanced investor dialogue under the TSE "cost of capital" initiative; updates were disclosed in May 2024 and May 2025.
5. R&D infrastructure. New R&D centre targeted for 2028; Tokyo Research Lab expanded.
6. Shareholder returns. Six consecutive years of dividend increases; FY2027 DPS forecast of JPY 28 post-split.
Initiatives in the last 24 months
| Date | Initiative | Detail |
|---|---|---|
| Jun 2024 | Group restructuring | Fuso Corporation business moved into the parent; entity dissolved 31 Mar 2026 |
| Oct 2024 | Kyoto new colloidal silica line | Completed; METI supply-chain subsidy of JPY 3,694 M approved Jun 2026 |
| May 2025 | Cost-of-capital disclosure update | ROE ≥10% commitment; cost-of-equity reassessment; IR enhancement |
| Aug–Dec 2025 | Kashima Phase 2 | JPY 20.7 bn; completed Aug 2025; full operation Dec 2025 |
| Mar 2026 | Kyoto JPY 40 bn plant | Approved 13 Mar 2026; start-up Feb 2029; JPY 403 M spent by end-FY2026 |
| Apr 2026 | 3:1 stock split | To improve liquidity and broaden the investor base |
| May 2026 | Next Growth 2030 | See 10.2 |
| 2,026 | PMP sodium gluconate expansion | — |
| Aug 2026 | Corporate Value Enhancement Committee; ROIC ≥13% target | Corporate presentation |
No quantified emissions-reduction target was verified in the sources reviewed.
Cost programmes: no formal cost-reduction programme with quantified targets has been disclosed.
Management guidance, FY2027
| Metric | FY2026 actual | FY2027 guidance (latest) | YoY |
|---|---|---|---|
| Net sales (JPY M) | 76,926 | 85,800 | +11.5% |
| Operating profit (JPY M) | 18,850 | 24,300 | +28.9% |
| Ordinary profit (JPY M) | 19,573 | 24,500 | +25.2% |
| Net income (JPY M) | 14,311 | 19,200 | +34.2% |
| EBITDA (JPY M) | 29,787 | about 37000 | +24.2% |
| EPS (JPY) | 135.28 | 181.48 | — |
| DPS (JPY) | 27.33 | 28.00 | — |
| H1 ordinary profit (JPY M) | 9,807 | 11,700 | — |
| H1 net income (JPY M) | 6,879 | 10,450 | — |
Notes on guidance:
-
Net income guidance was raised on 17 Jun 2026 from JPY 16,600 M to JPY 19,200 M because of the subsidy. EPS guidance was raised from JPY 156.90 to JPY 181.48.
-
Guidance excludes potential impacts of Middle East instability, per the May 2026 Tanshin.
Products & Services
Pricing models are not publicly disclosed for any product. All are negotiated B2B sales.
Electronic Materials Business
| Product / brand | Description & key capabilities | Target customer | Launch / latest |
|---|---|---|---|
| Quartron® ultra-high-purity colloidal silica (CMP grade) | Nano-scale silica particles in water, made by alkoxide synthesis. Very low metal impurities, tight particle-size-distribution control and reduced coarse particles. Used as the abrasive in CMP slurries for oxide, interconnect and other planarization steps. Third-party reports cite purity of up to 99.9999%, which is not company-verified. Envalith reports adoption in processes at the 1.8 nm node and beyond, citing company disclosures. | CMP-slurry formulators, e.g. FUJIFILM Electronic Materials Taiwan | Trial production 1987; capacity added at Kyoto 2005, 2007 and 2024, Kashima 2023 and 2025, and Kyoto new plant (2029) |
| Quartron® for silicon-wafer polishing | Colloidal silica grades for polishing prime silicon wafers (stock and final polish) | Wafer-polishing slurry makers and wafer producers | Long-established |
| Engineered-morphology colloidal silica | Particles with bent or branched (non-spherical) structures, high aggregation ratio, controlled density and alkoxy-group content. Designed for faster removal rates and lower defectivity. | Advanced-node slurry formulators | Covered by recent patent filings (IPqwery listing) |
| Hollow nano-silica | Hollow silica nanoparticles for anti-reflection and thermal insulation, aimed at diversifying away from semiconductors | Optical film and coating makers, insulation materials | Under development and early commercialisation (Annual Securities Report risk section) |
| Hydrophobic silica powder for toner | Surface-treated nano-silica powders as external additives for toner resin particles | Toner manufacturers | Patented; in commercial use (company recruitment disclosure) |
| Silica for resin additives and other functional uses | Nano-silica fillers for resins and coatings | Resin compounders | Commercial |
| Resin additives (isobutylene derivatives) | Historical "functional chemicals" products | Resin and polymer makers | Since 1966; formerly in the old segment name |
Life Science Business
| Product / brand | Description | Target customer | Launch / latest |
|---|---|---|---|
| Malic acid (food, FDA and industrial grades) | Acidulant for beverages, confectionery and processed foods; also industrial and pharma uses. Produced in Osaka (Sakai) and Kashima. | Food and beverage makers worldwide | 1962; FDA grade 1975; Kashima plant 2019 |
| Citric acid and sodium citrate | Crude citric acid refined in Qingdao to Japanese food-additive standards; also high-purity industrial grades | Food, beverage and industrial cleaning customers | 1986/1987; Qingdao refining since 1994 |
| Gluconic acid, sodium gluconate (PMP Fermentation Products, USA) | Fermentation-based products for concrete admixtures, metal surface treatment, cleaning and food. An expansion investment for sodium gluconate at PMP has been decided. | Construction chemicals and industrial customers in North America | Acquired 2003; expansion under way |
| Maleic anhydride, fumaric acid | Petrochemical-route organic acids for resins (unsaturated polyester), food acidulants (fumaric) and other uses | Resin makers, food | Acquired from Mitsui Chemicals Oct 2014 |
| Other fruit/organic acids | Lactic, tartaric, succinic, ascorbic, acetic and maleic acid (some traded) | Food industry | Ongoing |
| Food-additive preparations (FFA) | Blended functional preparations: antioxidant preparations, noodle-skin preparations, deli preparations, tofu preparations, shelf-life improvers | Japanese food processors | Ongoing; management priority for growth |
| "Aplucol" (アプルコール) | Alcohol-based food preservative preparation | Food processors | 1,981 |
| "W-Clean" (Wクリーン) | Algae-removal agent for nori (seaweed) aquaculture | Nori farmers | 1,982 |
| Coated organic acids | Encapsulated acids for controlled release in food processing | Bakery and confectionery makers | Expansion targeted under the current plan |
| High-purity organic acids | High-purity grades for electronics and pharma | Electronics and pharma customers | Ongoing |
| Stress-free preparations (ストレスフリー製剤) | Functional formulations; details not disclosed | Food and health | Listed in the company product overview |
Financial Detail
Segment Overview
| Segment | Contents | Key products |
|---|---|---|
Life Science Business (ライフサイエンス事業) | Fruit and organic acids for food, industrial and pharmaceutical uses; high-value-added applied products | Malic acid, citric acid and sodium citrate, gluconic acid and sodium gluconate (PMP, US), lactic/tartaric/succinic/ascorbic/acetic acids (some traded), maleic anhydride, fumaric acid, food-additive preparations (FFA), coated organic acids, high-purity organic acids, "stress-free" preparations |
Electronic Materials Business (電子材料事業) | Ultra-high-purity colloidal silica and silica functional materials | Quartron® ultra-high-purity colloidal silica (CMP abrasive raw material), hollow nano-silica, hydrophobic silica powders for toner, other silica functional materials |
Revenue by Segment
| Segment (JPY Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Life Science revenue | 34,143 | 36,288 | 35,411 |
Electronic Materials revenue (new definition) | — | 33,214 | 41,515 |
Electronic Materials & Functional Chemicals revenue (former definition) | 24,827 | — | — |
Consolidated revenue | 58,970 | 69,501 | 76,926 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment (JPY Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Life Science segment profit | 5,637 | 5,289 | 5,308 |
Electronic Materials segment profit (new definition) | — | 13,171 | 15,927 |
Electronic Materials & Functional Chemicals segment profit (former definition) | 7,533 | — | — |
Corporate / eliminations | -2,087 | -2,230 | -2,384 |
Consolidated operating profit | 11,083 | 16,230 | 18,850 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Life Science operating margin | 16.5 | 14.6 | 15.0 |
Electronic Materials operating margin | 30.3 | 39.7 | 38.4 |
Life Science revenue YoY growth | -9.7 | 6.3 | -2.4 |
Electronic Materials revenue YoY growth | -19.0 | 33.8 | 25.0 |
Life Science share of consolidated revenue | 57.9 | 52.2 | 46.0 |
Electronic Materials share of consolidated revenue | 42.1 | 47.8 | 54.0 |
Electronic Materials share of total segment profit | 57.2 | 71.3 | 75.0 |
Segment Assets & Liabilities
| Metric (JPY Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Electronic Materials segment assets | 63,186 | 72,608 | 72,708 |
Life Science segment assets | 38,713 | 38,548 | 40,402 |
Electronic Materials capex (incl. intangibles) | 11,575 | 14,567 | 7,926 |
Life Science capex (incl. intangibles) | 2,433 | 1,371 | 2,734 |
Electronic Materials depreciation | 5,337 | 6,522 | 9,095 |
Life Science depreciation | 1,616 | 1,570 | 1,638 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (JPY Mn) | 55,760 | 68,459 | 58,970 | 69,501 | 76,926 |
Cost of sales (JPY Mn) | 32,679 | 40,048 | 38,397 | 43,531 | 47,609 |
Gross profit (JPY Mn) | 23,081 | 28,411 | 20,573 | 25,971 | 29,317 |
SG&A (JPY Mn) | 8,046 | 9,480 | 9,489 | 9,740 | 10,466 |
Operating profit (JPY Mn) | 15,034 | 18,930 | 11,083 | 16,230 | 18,850 |
Depreciation & amortisation (JPY Mn) | 4,453 | 4,338 | 7,160 | 8,309 | 10,937 |
EBITDA (JPY Mn) | 19,488 | 23,268 | 18,244 | 24,539 | 29,787 |
Ordinary profit (JPY Mn) | 15,509 | 19,740 | 11,883 | 16,561 | 19,573 |
Pre-tax income (JPY Mn) | 15,713 | 20,082 | 12,006 | 16,267 | 19,528 |
Income taxes (JPY Mn) | 4,823 | 5,952 | 3,662 | 4,644 | 5,216 |
Net income attributable to owners (JPY Mn) | 10,890 | 14,129 | 8,343 | 11,622 | 14,311 |
Comprehensive income (JPY Mn) | 12,070 | 14,328 | 9,836 | 11,399 | 15,932 |
Per-Share Data and Key Financials (JPY)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EPS basic, post-split (JPY) | 102.69 | 133.63 | 78.90 | 109.89 | 135.28 |
EPS diluted, post-split (JPY) | 102.69 | 133.63 | 78.90 | 109.89 | 135.28 |
DPS, post-split (JPY) | 18.33 | 21.00 | 22.00 | 24.33 | 27.33 |
DPS, pre-split as declared (JPY) | 55 | 63 | 66 | 73 | 82 |
BPS, post-split (JPY) | 712.21 | 827.60 | 898.59 | 983.72 | 1,107.94 |
Margin Analysis (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin | 41.4 | 41.5 | 34.9 | 37.4 | 38.1 |
Operating margin | 27.0 | 27.7 | 18.8 | 23.4 | 24.5 |
EBITDA margin | 34.9 | 34.0 | 30.9 | 35.3 | 38.7 |
Net margin | 19.5 | 20.6 | 14.1 | 16.7 | 18.6 |
Revenue growth YoY | 32.1 | 22.8 | -13.9 | 17.9 | 10.7 |
Effective tax rate | 30.7 | 29.6 | 30.5 | 28.5 | 26.7 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (JPY Mn) | 92,010 | 113,529 | 133,740 | 141,502 | 152,256 |
Cash & deposits (JPY Mn) | 24,236 | 23,412 | 31,471 | 31,295 | 41,006 |
Short-term borrowings incl. current portion of LTD (JPY Mn) | 0 | 0 | 0 | 3,100 | 4,000 |
Long-term debt (JPY Mn) | 0 | 0 | 20,000 | 16,900 | 12,900 |
Total debt (JPY Mn) | 0 | 0 | 20,000 | 20,000 | 16,900 |
Net debt (JPY Mn; negative = net cash) | -24,236 | -23,412 | -11,471 | -11,295 | -24,106 |
Net assets / equity (JPY Mn) | 75,303 | 87,503 | 95,025 | 104,049 | 117,217 |
Intangible assets incl. goodwill (JPY Mn) | 1,904 | 1,346 | 3,129 | 4,006 | 5,490 |
Inventories (JPY Mn) | 11,978 | 16,040 | 17,416 | 18,153 | 18,409 |
Trade receivables (JPY Mn) | 14,872 | 14,954 | 16,445 | 16,032 | 16,610 |
Total current assets (JPY Mn) | 52,078 | 55,344 | 68,133 | 67,052 | 78,476 |
Total current liabilities (JPY Mn) | — | — | — | 18,490 | 19,844 |
Working capital (JPY Mn) | — | — | — | 48,562 | 58,632 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (JPY Mn) | 10,199 | 13,926 | 7,061 | 22,702 | 24,794 |
Capital expenditure, cash (JPY Mn) | 9,226 | 13,433 | 14,944 | 18,354 | 7,349 |
Free cash flow (JPY Mn) | 973 | 493 | -7,883 | 4,348 | 17,445 |
Investing cash flow (JPY Mn) | -9,375 | -13,418 | -18,576 | -20,538 | -11,069 |
Dividends paid (JPY Mn) | 1,769 | 2,114 | 2,325 | 2,396 | 2,785 |
Share buybacks (JPY Mn) | 1,108 | 0 | 1 | 1 | 0 |
Debt issued (JPY Mn) | 0 | 0 | 20,000 | 0 | 0 |
Debt repaid (JPY Mn) | 0 | 0 | 0 | 0 | 3,100 |
Financing cash flow (JPY Mn) | -2,882 | -2,125 | 17,664 | -2,409 | -5,905 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | 15.4 | 17.4 | 9.1 | 11.7 | 12.9 |
ROA, net income / total assets (%) | 11.8 | 12.4 | 6.2 | 8.2 | 9.4 |
ROIC, company definition (%) | — | — | — | — | 11.1 |
Current ratio (x) | — | — | — | 3.63 | 3.95 |
Debt / equity (x) | 0.00 | 0.00 | 0.21 | 0.19 | 0.14 |
Net debt / EBITDA (x) | -1.24 | -1.01 | -0.63 | -0.46 | -0.81 |
Interest coverage, OP / interest expense (x) | — | — | 91.6 | 123.9 | 153.3 |
Asset turnover (x) | 0.61 | 0.60 | 0.44 | 0.49 | 0.51 |
Days sales outstanding (days) | 97.4 | 79.7 | 101.8 | 84.2 | 78.8 |
Days inventory outstanding (days) | 133.8 | 146.2 | 165.6 | 152.2 | 141.1 |
Days payables outstanding (days) | 34.0 | 30.0 | 22.4 | 25.8 | 21.7 |
Cash conversion cycle (days) | 197.2 | 195.9 | 245.0 | 210.6 | 198.2 |
Revenue by Region and Revenue by Region (%)
| Region (JPY Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Japan | 29,551 | 34,056 | 31,272 | 34,311 | 34,531 |
Asia | 14,967 | 21,326 | 17,038 | 23,544 | 29,500 |
North America | 10,115 | 11,435 | 9,992 | 10,809 | 12,127 |
Europe | 939 | 1,404 | 547 | 730 | 675 |
Other | 188 | 239 | 121 | 107 | 94 |
Overseas sales ratio (%) | 47.0 | 50.3 | 47.0 | 50.6 | 55.1 |
Region growth YoY (%)
| Region growth YoY (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Japan | -8.2 | 9.7 | 0.6 |
Asia | -20.1 | 38.2 | 25.3 |
North America | -12.6 | 8.2 | 12.2 |
Europe | -61.0 | 33.5 | -7.5 |
Other | -49.4 | -11.6 | -12.1 |
Share Price History
| Date | Price (JPY) | Note | Source |
|---|---|---|---|
6 Jan 2026 | 2,107 | Year-to-date low per Yahoo! Finance. Traders Web shows a ¥2,632 low on 31 Mar 2026; the two sources use different split adjustments. | Yahoo! Finance JP; Traders Web |
3 Feb 2026 | 2,517 | Split-adjusted close | Kabutore |
31 Mar 2026 | 2,726 | FY-end price (company) | Corporate presentation, Aug 2026 |
22 Jun 2026 | 4,995 | Year-to-date high | Yahoo! Finance JP |
10 Jul 2026 | 4,040 | — | Yahoo! Finance JP |
10 Aug 2026 | 3,355 | -11.9% post-Q1 | Traders Web |
17 Sep 2026 | 2,913 | — | Kabuyoho |
30 Sep 2026 | 3,220 | Latest verified close | Monex Scouter |
Valuation Multiples
| Multiple | Fuso Chemical | Nissan Chemical (reference) |
|---|---|---|
P/E, trailing (FY2026 EPS 135.28) | 23.8x | 16.3x (EDINET DB snapshot) |
P/E, forward (FY2027 company EPS 181.48) | 17.7x (Monex) | — |
P/E, forward excluding subsidy (EPS about 156.9) | 20.5x | — |
EV/EBITDA, FY2026 (EV about JPY 318.9 bn) | 10.7x | — |
EV/EBITDA, FY2027E (EBITDA about JPY 37.0 bn) | 8.6x | — |
EV/Sales, FY2026 | 4.1x | — |
P/B (actual) | 2.77x (Monex) | 3.15x (EDINET DB snapshot) |
Dividend yield (FY2027E JPY 28) | 0.87% | 3.37% (EDINET DB snapshot) |
Capital Markets
| Item | Value | Source |
|---|---|---|
Rating (average) | 4.75 / 5 (bullish) | Kabuyoho (Sep 2026) |
Average target price | JPY 6,350. Treat with caution; it may include stale or unadjusted targets. | Kabuyoho |
FY2027 consensus sales | JPY 90,420 M | Kabuyoho (Aug 2026) |
FY2027 consensus operating profit | JPY 25,770 M | Kabuyoho |
FY2027 consensus ordinary profit | JPY 26,053–26,495 M (varies by date) | Kabuyoho |
FY2027 consensus net income | JPY 20,438 M | Kabuyoho |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | FY2027 |
|---|---|---|---|---|---|---|
DPS, post-split (JPY) | 18.33 | 21.00 | 22.00 | 24.33 | 27.33 | 28.00 |
Payout ratio (%) | 17.9 | 15.7 | 27.9 | 22.1 | 20.2 | 15.4 |
Capital Markets — Credit ratings
| Item | Detail |
|---|---|
Credit ratings (Moody's / S&P / Fitch) | None identified; the company does not appear to be publicly rated. No R&I or JCR rating was identified either. |
Debt instruments | Bank term loan of JPY 20,000 M drawn in FY2024; no bonds |
Outstanding at 31 Mar 2026 | JPY 16,900 M (JPY 4,000 M due within one year; JPY 12,900 M long-term) |
Repayment history | JPY 3,100 M repaid in FY2026 |
Maturity profile beyond FY2027 | On a straight-line basis (analyst assumption), the remaining JPY 12.9 bn amortises over about 3–4 years. |
Interest expense | JPY 123 M in FY2026 (about 0.7% implied rate) |
Analyst Conclusions
Guidance versus consensus
| Metric | FY2026 actual | FY2027 company guidance | FY2027 consensus | FY2031 plan |
|---|---|---|---|---|
| Net sales (JPY M) | 76,926 | 85,800 | 90,420 | 120,000 |
| Operating profit (JPY M) | 18,850 | 24,300 | 25,770 | 36,000 |
| Net income (JPY M) | 14,311 | 19,200 | 20,438 | — |
Consensus sits about 5–6% above company guidance. That is consistent with management's history of conservative initial guidance (FY2025: initial OP guidance JPY 11.15 bn, actual JPY 16.23 bn).
Bull case
-
Volume ramp is already visible.
-
Q1 FY2027 sales rose 22.3% and OP 31.5%. Q1 delivered 26.0% of full-year ordinary-profit guidance.
-
Kashima Phase 2 entered full operation only in Dec 2025, and its qualification-driven volume is still ramping.
-
That makes the FY2027 OP guide of JPY 24.3 bn look achievable, with upside toward consensus of JPY 25.8 bn.
-
-
Structural CMP-intensity growth plus near-monopoly economics.
-
Electronic Materials generated about 60% segment EBITDA margins in FY2026.
-
With the dominant share of a niche that adds CMP steps at every node and in HBM, incremental capacity (Kyoto 2029) should earn returns well above the 8–9% cost of equity. That supports the ROIC ≥13% target.
-
-
Valuation reset and balance-sheet optionality.
-
After the 36% drawdown from June, the stock trades at about 17.7x company-guided FY2027 EPS and about 8.6x FY2027E EV/EBITDA, with net cash.
-
A modest payout increase or buyback would address the low 0.87% yield and the PBR-2.5x KPI.
-
Bear case
-
Cyclical peak risk.
-
FY2024 showed how fast earnings can fall: OP -41% on a memory downturn plus inventory correction.
-
The market sold the stock 12% on the H1 guide, which implies Q2 ordinary profit of about JPY 5.3 bn against JPY 6.4 bn in Q1, a sequential slowdown.
-
If AI capex digestion arrives in 2027, new capacity will be under-utilised just as depreciation rises.
-
-
Capex-heavy plan with a credibility gap.
-
The previous plan missed its sales target by about 9.5%.
-
The new plan needs +56% sales and +91% OP in five years.
-
The JPY 40 bn Kyoto project (about 34% of equity) does not contribute until FY2029–FY2030 and will add about JPY 3–4 bn a year of depreciation (analyst estimate). FCF will compress again in FY2027–FY2029.
-
-
Concentration and localisation risk, plus a stagnant second leg.
-
One customer accounts for 13.9% of sales.
-
Chinese high-purity silica suppliers are emerging under state support.
-
Life Science profit has been flat at about JPY 5.3 bn for three years and faces Chinese overcapacity.
-
The "two-pillar" story therefore leans entirely on semiconductors.
-
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
| Late Oct 2026 | H1 FY2027 results | Q2 ordinary profit against the implied about JPY 5.3 bn; any full-year guidance raise; Electronic Materials margin |
| Ongoing | Kashima Phase 2 qualification progress | Customer approvals and utilisation commentary |
| Ongoing | Kyoto JPY 40 bn construction | Cost and schedule versus the Feb 2029 start-up; any shift to borrowing |
| Feb 2027 | Q3 FY2027 results | Run-rate toward the JPY 24.3 bn OP guide |
| May 2027 | FY2027 results and FY2028 guidance | First-year progress on Next Growth 2030; dividend policy |
| 2026–2027 | Capital policy | Buybacks or payout increase to meet PBR and ROIC KPIs |
| Macro | AI and HBM capex; memory pricing; JPY/USD | Leading indicators for silica demand and translation |
| Competitive | Chinese colloidal-silica qualification wins | Share-erosion risk |
| Life Science | China and Europe demand; PMP expansion | Return to segment-profit growth |
Analyst verdict
Business quality. Fuso Chemical is a high-quality, under-followed global niche leader. It is going through its most consequential capital cycle since founding.
-
Its Electronic Materials franchise is the world's leading supplier of ultra-high-purity colloidal silica for CMP. On disclosed segment data it earns about 38% operating and about 60% EBITDA margins.
-
Those economics are protected by purity know-how, long qualification histories and policy recognition, as the June 2026 METI subsidy shows.
-
The balance sheet carries net cash and a 77% equity ratio, so the JPY 40 bn Kyoto expansion is financially comfortable.
What the investment case depends on. The case is no longer about whether Fuso has a moat; it does. It is about three things:
Timing: filling Kashima Phase 2 before the next semiconductor down-cycle.
Discipline: delivering Kyoto on budget by Feb 2029 and lifting ROIC from 11.1% to at least 13%.
Capital allocation: the current roughly 20% payout and absent buybacks sit awkwardly with a stated PBR-2.5x KPI.
Execution record. FY2024 is the stress test to remember: revenue fell 14% and OP 41% in a single year. The previous medium-term plan's sales miss tempers confidence in the JPY 120 bn FY2031 target. Against that, management guides conservatively; FY2025 OP beat the initial guide by 46%. Q1 FY2027 was strong and above consensus.
Valuation. After the post-Q1 sell-off, the shares trade at about 17.7x guided FY2027 EPS, about 20.5x excluding the one-off subsidy, and about 8.6x FY2027E EV/EBITDA. That is reasonable for a business compounding segment EBITDA in the high teens, albeit with cyclical beta.
Overall view: constructive, with a cyclical risk overlay. The stock is best owned by investors with conviction in multi-year CMP intensity growth from AI and HBM, who can tolerate drawdowns of 30–40% such as the one seen in 2026.
Key upside triggers:
-
evidence of price increases sticking;
-
faster Kashima qualification;
-
a shift in shareholder returns.
Key downside triggers:
-
a sequential Electronic Materials slowdown in H1 results;
-
any slippage or overrun at Kyoto;
-
a qualified Chinese competitor at a major slurry customer.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Background / prior roles | AGM approval % (Jun 2026) | Independent |
|---|---|---|---|---|
Shinichi Sugita (杉田 真一) | Representative Director, President & CEO (since 2020) | Joined Fujisawa Pharmaceutical (now Astellas) in Apr 1980; joined Fuso through the 2003 acquisition of Fujisawa's chemicals business | 95.78 | No |
Misako Fujioka (藤岡 実佐子) | Representative Director, Chairman | Outside director of Fuso from Jun 1988; long-serving board member; individual shareholder (3.0–3.25% in historical filings) | 96.50 | No |
Haruo Masauji* (政氏 晴生) | Senior Managing Director, GM Life Science Business Unit | Joined Fuso Apr 1990; previously GM Electronic Materials Business Unit and in charge of innovation | 98.49 | No |
Motoki Sugimoto (椙本 源樹) | Director, GM Electronic Materials Business Unit | Joined Fuso Apr 1992; previously GM Life Science | 98.49 | No |
Atsushi Fujioka* (藤岡 篤) | Managing Director, GM Corporate Planning | Joined Fuso Nov 2019 | 98.59 | No |
Hiroyuki Ito (伊藤 裕之) | Director, GM Administration Headquarters | Former Senior Executive Officer, Administration | 98.48 | No |
Norikazu Miyamoto* (宮本 典和) | Director, GM Production Headquarters | — | 98.48 | No |
Sayaka Eguro* (江黒 早耶香) | Director, Audit & Supervisory Committee Member | Attorney; registered with Daiichi Tokyo Bar Association in 2008; Soga, Uryu & Itoga | 99.43 | Yes |
百嶋 計 | Outside Director | Joined Ministry of Finance in 1981 | 99.30 | Yes |
Takashi Takeuchi* (武内 敬) | Director, Audit & Supervisory Committee Member | Joined Osaka Gas in 1987 | 99.35 | Yes |
Toshihide Tominaga* (富永 俊秀) | Director (newly elected Jun 2026) | — | 99.50 | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1957–2018 | Founder Shozo Akazawa leads | Founder era. The Shashi also records Ryota Akazawa as president around FY2019; sources conflict on the exact 2018–2019 sequence. |
| 2018 | Yoshinobu Nakano (ex-Inabata & Co.) becomes President | First non-family professional CEO |
| 2020 | Shinichi Sugita becomes President & CEO | Presided over the Kashima/Kyoto capacity build and the AI-cycle earnings records |
2018 onward (various) | Departed directors: Takashi Tanimura (Senior Managing Director, international), Tomomi Tada (ex-Teikoku Seiyaku), and several Audit & Supervisory Committee members | Routine rotation |
Jun 2026 | Toshihide Tominaga elected | Board strengthening alongside the new plan |
Directors' Remuneration
| Metric (JPY Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total director remuneration (JPY Mn) | 303 | 312 | 285 | 364 | 389 |
Fixed remuneration (JPY Mn) | 169 | 171 | 177 | 208 | 192 |
Bonus (JPY Mn) | 134 | 141 | 86 | 126 | 164 |
Stock-based (JPY Mn) | 0 | 0 | 21 | 30 | 33 |
Number of directors covered | 6 | 6 | 6 | 6 | 8 |
Major Shareholders
| Rank | Shareholder | Type | Stake (%) |
|---|---|---|---|
| 1 | 壽世堂 (Jusei-do), Akazawa-family-linked asset company (inferred, not confirmed) | Strategic / founding family | 15.87 |
| 2 | Teikoku Seiyaku Co., Ltd. (origin parent) | Strategic | 9.44 |
| 3 | The Master Trust Bank of Japan (trust a/c) | Custodian / institutional | 9.19 |
| 4 | 薫風舎 (Kunpu-sha), private holding company (inferred, not confirmed) | Strategic / family | 7.43 |
| 5 | Custody Bank of Japan (trust a/c) | Custodian / institutional | 6.52 |
| 6 | Osaka Small and Medium Business Investment & Consultation Co. | Financial | 4.23 |
| 7 | 有限会社帝産 (Teisan) | Strategic (Teikoku-linked, inferred) | 3.90 |
| 8 | The Bank of New York Mellon 140042 | Foreign custodian | 2.86 |
| 9 | Akazawa Memorial Foundation (公益財団法人赤澤記念財団) | Foundation (founder-linked) | 2.84 |
| 10 | US Bank National Association JP Accts TS | Foreign custodian | 2.01 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | HQ | Relevant products | Relative positioning |
|---|---|---|---|---|
Electronic Materials | Nissan Chemical Corp. (TSE 4021) | Japan | "Snowtex" colloidal silica; semiconductor materials (ARC, resist underlayers) | Broad-based; strong in colloidal silica, but Fuso is seen as the leader in ultra-high-purity alkoxide CMP grade |
Electronic Materials | Merck KGaA (EMD Electronics, incl. ex-Versum) | Germany | Colloidal silica and CMP slurries | Integrated slurry and abrasive capability |
Electronic Materials | Evonik Industries | Germany | Fumed and colloidal silica; CMP-grade colloidal silica capacity | Expanding CMP-grade supply |
Electronic Materials | Nouryon (Levasil) | Netherlands/Sweden | Colloidal silica (mostly industrial; some electronics) | Volume leader in industrial grades |
Electronic Materials | W. R. Grace (LUDOX) | USA | Colloidal silica | Industrial and specialty; building high-purity offer |
Electronic Materials | Ecolab / Nalco | USA | Colloidal silica | Industrial |
Electronic Materials | Shanghai Xin'anna Electronic Technology; Suzhou Nanodispersions | China | High-purity colloidal silica | Emerging domestic Chinese suppliers, a localisation threat |
Electronic Materials (adjacent) | Fujimi Inc.; Entegris (CMC Materials); Resonac; Fujifilm | Japan/USA | CMP slurries | Customers who could vertically integrate into abrasive synthesis |
Life Science | Bartek Ingredients | Canada | Malic and fumaric acid | Major North American malic producer |
Life Science | Polynt | Italy | Malic acid, maleic anhydride | European competitor |
Life Science | Thirumalai Chemicals | India | Malic acid, maleic anhydride | Low-cost Asian competitor |
Life Science | Changmao Biochemical and other Chinese producers | China | Malic and other acids | Price-setting Chinese capacity |
Life Science | Jungbunzlauer | Switzerland | Citric acid, gluconates | Global citric and gluconate leader |
Life Science | Weifang Ensign, COFCO Biochemical, Shandong producers | China | Citric acid | Dominant global citric-acid supply |
Life Science | Roquette; ADM; Cargill | France/USA | Gluconates and fermentation acids | Gluconate competitors to PMP |
Competitor Detail
| Source | Estimate |
|---|---|
ReportPrime (Apr 2026) | Fuso reportedly supplies about 90% of CMP-grade colloidal-silica raw abrasive. Market size estimated at US$258.6 M in 2025. |
ReportPrime company-ranking page | Nissan Chemical, Fuso and Cabot together hold about 45%; market US$240 M in 2024; 7.73% CAGR |
Industry blog citing a market report | Fuso, Merck and Evonik together hold about 68% of high-purity colloidal silica |
DCF-analysis SWOT (Apr 2026) | Fuso holds more than 50% of ultra-high-purity colloidal silica (late 2025) |
Peer Comparison FY2027
| Metric | Fuso Chemical | Nissan Chemical |
|---|---|---|
Revenue (JPY Mn or as stated) | 76,926 | 279,586 |
Revenue growth YoY (%) | 10.7 | 11.2 |
Operating margin (%) | 24.5 | 22.7 |
ROE (%) | 12.9 | 20.3 |
Equity ratio (%) | 77.0 | 71.9 |
Recent Developments
*Note on the 10 Aug 2026 reaction. The company gave no specific explanation.
H1 ordinary-profit guidance of JPY 11.7 bn implies Q2 of only about JPY 5.3 bn after a JPY 6.4 bn Q1.
Both the H1 and full-year guides sit 6–8% below consensus.
The market read this as a sequential slowdown and possibly management conservatism.



